July 09, 2014 10:57 PM ET

Company Overview of The University of Massachusetts Medical School

Company Overview

55 Lake Avenue North

Worcester, MA 01655

United States



Key Executives for The University of Massachusetts Medical School

Director for Diabetes Center of Excellence and Division Chief of Diabetes
Director for the Cancer Center of Excellence
Senior Director of Human Stem Cell Bank & Registry
Compensation as of Fiscal Year 2014.

The University of Massachusetts Medical School Key Developments

UMass Medical School Receives Multi-Million Dollar Contract to Manage Health Care at Federal Correctional Institution in New York

The Federal Bureau of Prisons has awarded the University of Massachusetts (UMass) Medical School a multimillion dollar contract to manage comprehensive medical services for nearly 1,000 inmates at the Federal Correctional Institution (FCI) located in Ray Brook, New York. The five-year agreement is valued at a total of $8 million, and becomes UMass Medical School's fourth federal correctional health contract. The Health and Criminal Justice Program, part of UMass Medical School's Commonwealth Medicine division, will manage the contract. The medical school's work at FCI Ray Brook will in the month June. The contract calls for UMass Medical School to coordinate inpatient and outpatient care provided by specialist physicians at the correctional facility and in community settings. The medical school will manage scheduling and handle all claims associated with the care.

University of Massachusetts Medical School Wins $7.98 Million Federal Contract

University of Massachusetts Medical School won a $7,979,958.52 federal contract from the U.S. Department of Justice's Bureau of Prisons, Grand Prairie, Texas, for comprehensive medical services.

Amarantus Bioscience Holdings, Inc Signs License Agreement with University of Massachusetts Medical School

Amarantus Bioscience Holdings Inc. has entered into an exclusive worldwide license agreement with University of Massachusetts Medical School (UMMS) for intellectual property surrounding the use of mesencephalic astrocyte-derived neurotrophic factor (MANF) as both a biomarker and a treatment for beta cell-degenerating disorders. Both the entities are based in the US. The license agreement includes all intellectual property covering the use of MANF as a biomarker and treatment for beta cell degeneration disorders, including wolfram syndrome, Type-1 diabetes and Type-2 diabetes. Deal Rationale: The transaction expands Amarantus' intellectual property portfolio for MANF, including composition of matter and method of use patents and patent applications worldwide for MANF and derivative sequences for protein therapy, gene therapy and cell therapy applications.

Similar Private Companies By Industry

Company Name Region
Petro Source Corporation United States
Home Technologies, Inc. United States
National Bank of America, Salina Kansas United States
Berkowits & Company, PA United States
Equity Bank Holding Co., Inc. United States

Recent Private Companies Transactions

No transactions available in the past 12 months.

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup

Most Searched Private Companies

Company Name Geographic Region
Bertelsmann AG Europe
Lawyers Committee for Civil Rights Under Law United States
NYC2012, Inc. United States
Rush University United States
Citizens Budget Commission United States

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact The University of Massachusetts Medical School, please visit www.umassmed.edu. Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.